NEW YORK: Affymetrix and Cytox have agreed to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI).
The value of the collaboration was not disclosed by Cytox, which announced the Read More »